Target intelligence / Profile preview

Human immunodeficiency virus type 1 Nef, Tat, and Vif proteins (HIV-1 Nef/Tat/Vif)

Target
HIV-1 Nef/Tat/Vif
Molecular classification
Viral protein, Accessory protein, Regulatory protein, Transcription factor, E3 ubiquitin ligase substrate receptor
01

Overview

HIV-1 Nef, Tat, and Vif are essential non-structural proteins that coordinate the viral life cycle and host immune subversion. Tat is a potent transactivator of the viral LTR promoter, required for efficient transcription of the HIV genome by binding to the TAR RNA element [3, 6]. Nef acts as a major virulence factor by downregulating host cell surface receptors, such as CD4 and MHC-I, which promotes viral spread and allows infected cells to evade cytotoxic T lymphocyte recognition [1, 9]. Vif is critical for viral infectivity as it neutralizes the host's innate antiviral defense by targeting the APOBEC3G protein for proteasomal degradation [4, 6]. These proteins are frequently targeted in multi-antigen therapeutic vaccines, such as the HIV-MAG DNA vaccine, to elicit broad cellular immune responses and potentially clear the latent viral reservoir [27, 34]. Experimental small molecules, including Nef-specific hydroxypyrazoles and Tat-inhibiting cortistatin analogs, are also under investigation to disrupt these viral functions [10, 37].

Other names
HIV-1 accessory and regulatory proteinsNef-Tat-Vif fusion proteinHIV-1 Nef/Tat/Vif antigensNefTatVif
02

Mechanism of action

Tat binds to the TAR RNA element to transactivate the viral LTR promoter, driving high-level transcription; Nef downregulates CD4 and MHC-I from the cell surface via endosomal trafficking to facilitate viral release and immune escape; Vif recruits the Cullin-5 E3 ubiquitin ligase complex to degrade host APOBEC3G, preventing viral genome mutagenesis.

03

Biological functions

Viral replicationImmune evasionTranscription activationAPOBEC3G degradationCD4 downregulationMHC-I downregulationViral infectivity enhancement
04

Disease associations

InfectionAIDS
05

Safety considerations

Viral escape mutationsImmune-mediated inflammationOff-target toxicity of small molecule inhibitorsPotential for vaccine-induced seropositivity (VISP)
06

Interacting drugs

HIV-MAG (DNA vaccine)

5 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-cell countIFN-gamma ELISpot responseMHC-I surface expression

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 Nef, Tat, and Vif proteins (HIV-1 Nef/Tat/Vif).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 Nef, Tat, and Vif proteins (HIV-1 Nef/Tat/Vif).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call